The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Risk Factors for Loss of Visual Acuity among Patients with Uveitis Associated with Juvenile Idiopathic Arthritis: The Systemic Immunosuppressive Therapy for Eye Diseases Study
Open accessAbstract
Purpose To describe the incidence of and risk factors for visual acuity (VA) loss and ocular complications in patients with juvenile idiopathic arthritis (JIA)-associated uveitis. Design Multicenter retrospective cohort study. Participants 327 patients (596 affected eyes) with JIA-associated uveitis managed at five tertiary uveitis clinics in the United States. Methods Participants were identified from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Demographic and clinical characteristics were obtained for every eye of every patient at every visit via medical record review by trained expert reviewers. Main Outcome Measures Loss of VA to 20/50 or to 20/200 or worse thresholds and the development of ocular complications. Results At presentation, 240 (40.3%) eyes had a VA of 20/50 or worse; 144 (24.2%) had a VA of 20/200 or worse; 359 (60.2%) had at least one ocular complication. The incidences of VA loss to the 20/50 or worse and 20/200 or worse thresholds were 0.18 and 0.09 per eye-year (EY), respectively; the incidence of developing at least one new ocular complication over follow-up was 0.15/EY (95% confidence interval [CI]: 0.13/EY, 0.17/EY). However, among eyes with uveitis that had no complications at presentation, the rate of developing at least one ocular complication during follow up was lower (0.04/EY, 95% CI: 0.02, 0.06). Posterior synechiae, active uveitis, and prior intraocular surgery were statistically significantly associated with VA to the 20/50 or worse and 20/200 or worse thresholds, both at presentation and during follow-up. Increasing (time-updated) anterior chamber cell grade was associated with increased rates of visual loss in a dose-dependent fashion. Use of immunosuppressive drugs was associated with a reduced the risk of visual loss, particularly for the 20/50 or worse outcome (hazard ratio = 0.40, 95% CI: 0.21, 0.75, P<0.01). Conclusions Ocular complications and vision loss were common in our cohort. Increasing uveitis activity was associated with increased risk of vision loss and use of immunosuppressive drugs was associated with reduced risk of vision loss suggesting that control of inflammation and use of immunosuppression may be critical aspects in improving the outcomes of patients with JIA-related uveitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mycophenolate Mofetil Therapy for Inflammatory Eye Disease
Thorne, J. E., Jabs, D. A., Qazi, F. A., Nguyen, Q. D., Kempen, J. H., & Dunn, J. P. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.020 · Cited by 219
Self-citationGalor, A., Jabs, D. A., Leder, H. A., Kedhar, S. R., Dunn, J. P., Peters, G. B., & Thorne, J. E. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.04.026 · Cited by 217
Self-citation
Cited by
Angeles‐Han, S. T., Ringold, S., Beukelman, T., Lovell, D., Cuello, C. A., Becker, M. L., Colbert, R. A., Feldman, B. M., Holland, G. N., Ferguson, P. J., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23871 · Cited by 316
Efficacy of high-dose methotrexate in pediatric non-infectious uveitis
Wieringa, W. G., Armbrust, W., Legger, G. E., & Los, L. I. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2018.1529800 · Cited by 17
Metadata
- Authors
- Gregory, A. C., Kempen, J. H., Daniel, E., Kaçmaz, R. O., Foster, C. S., Jabs, D. A., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., & Thorne, J. E.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 120
- Issue
- 1
- Pages
- 186-192
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2003095957
- Cited by
- 182
- References
- 2
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk Factors for Loss of Visual Acuity among Patients with Uveitis Associated with Juvenile Idiopathic Arthritis: The Systemic Immunosuppressive Therapy for Eye Diseases Study. https://app.cochat.ai/papers/10.1016/j.ophtha.2012.07.052
- The paper
- Gregory, A. C., Kempen, J. H., Daniel, E., Kaçmaz, R. O., Foster, C. S., Jabs, D. A., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., & Thorne, J. E. (2013). Risk Factors for Loss of Visual Acuity among Patients with Uveitis Associated with Juvenile Idiopathic Arthritis: The Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. https://doi.org/10.1016/j.ophtha.2012.07.052
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.